News

FT011 is a first-in-class oral therapy designed to treat chronic fibrosis in multiple organs. It is currently progressing through clinical development for the treatment of scleroderma. It acts

NICE has released the final draft guidance (FDG) that suggests Brukinsa as a recommended treatment for eligible adults with untreated CLL if there is a 17p deletion or

PCI will be responsible for the formulation, packaging, and distribution of a siRNA-based investigational injectable treatment for inflammatory dermatological conditions. The organisation will carry out all these activities

Maxigesic IV, which is a combination of 1000mg paracetamol and 300mg ibuprofen solution, is given intravenously to adults for relieving mild to severe pain. It received approval for

The NDA has been submitted based data from the randomised Phase III MARCH PFIC study of LIVMARLI. A total of 93 patients with various generic PFIC subtypes including

Following this approval, Knight expects to launch Minjuvi in Brazil in Q2 2024. In July this year, Agência Nacional de Vigilância Sanitária (ANVISA) granted market authorisation under the

CHMP also recommended approval of the anti-programmed death receptor-1 (PD-1) therapy. It recommended approval of KEYTRUDA along with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for locally advanced

With this expansion and added production line, the company can now offer more plasmid material in quality and GMP grades as well as extend the mRNA supply services.

The multicentre, open-label study will evaluate the autologous fully human anti-cd19 chimeric antigen receptor (CAR) T cell therapy KYV-101 in adult scleroderma patients. Kyverna Therapeutics CEO Peter Maag